Type of Event: Q2 and H1 FY27 Earnings Conference Call conducted on November 3, 2026.
Date and Time: November 3, 2026 (time not specified in the transcript).
Purpose: Discussion of quarterly results for the quarter and half year ended September 30, 2026, and business update.
Management Participants: Mr. Saharsh Davuluri (Chief Executive Officer & Managing Director), Mr. G.V. Bhardwaj (Assistant Vice President - Finance), Mr. Sajeev Medikonda (Head of Corporate Planning & Strategy). Mr. Abhijit Majumdar (CFO) was absent due to personal exigencies. The call was moderated by Runjhun Jain from Ernst & Young.
Availability of Materials: The transcript of the call has been uploaded on the company's website at: https://www.neulandlabs.com/en/investors/investor-meetings/transcripts. An investor presentation was referenced as having been shared along with the press release.
UPSI Statement: No explicit statement regarding unpublished price sensitive information was included in the provided transcript.
Financial Highlights Discussed
Financial Period: Quarter and Half Year ended September 30, 2026 (Q2 FY27 & H1 FY27).
Q2 FY27 Financials: Total Income stood at ₹457.2 Crores (vs. ₹516.1 Cr in Q2 FY26). Gross Margin was 59.4% (vs. 60.1%). EBITDA was ₹104.6 Crores (22.9% margin vs. ₹156.9 Cr, 30.4%). Profit After Tax was ₹51.1 Crores (vs. ₹96.5 Cr). EPS was ₹39.85 per share.
H1 FY27 Financials: Total Income stood at ₹1,107.2 Crores (vs. ₹816.7 Cr in H1 FY26).
Cash Flow & Capex: Capex outflow for H1 FY27 was ₹261 Crores. Free Cash Flow was ₹99 Crores. Net Debt was negative ₹208 Crores.
Working Capital: Increased to 104 days of sale from 84 days in the previous quarter.
Business Drivers: Revenues were predominantly driven by commercial molecules in the Contract Manufacturing Services (CMS) business and products from the Prime portfolio within the Generic Drugs and Services (GDS) business.
Strategic Updates: Management indicated that growth expectations remain intact for FY27 and the following financial year (FY28). The first half was largely in line with internal expectations.
Operational and Strategic Commentary
Peptide Facility: Commissioned a new peptide API manufacturing block at Unit One. Expected to see PPQ (Process Performance Qualification) related revenues in 6-9 months, with commercial revenues potentially 1.5-2 years away.
Expansion: Acquired approximately 134 acres of land at Kakinada, Andhra Pradesh, for future long-term expansion. The Board also approved investment to acquire more land around the existing Unit I.
R&D Center: Planning to inaugurate a new process R&D center at Genome Valley, Hyderabad, expected to be fully operational by early next year. It will focus on integrated process development for small molecules and peptides.
DMF Filings: Filed 2 Drug Master Files (DMFs) during the period for Fezolinetant and Ivacaftor.
Pipeline: Noted strong RFP (Request for Proposal) activity, described as the strongest to date. The number of Phase 3 projects increased from 8 to 13.
Challenges: Cited geopolitical turbulence leading to volatility in raw material prices and escalation in freight and logistics costs. Acknowledged the inherent lumpiness of the CDMO business due to the timing of large commercial shipments.
Customer Concentration: Top 5 customers contributed 68% of revenues.
Additional Notes Section
The document provided is the full transcript of the earnings conference call, submitted as a regulatory filing pursuant to Regulation 30 of SEBI LODR Regulations, 2015.
The transcript includes a detailed Q&A session with analysts covering topics such as the peptide business strategy, patent cliffs of key molecules, impact of AI on drug discovery, and working capital management.
No new financial data beyond what was presented in the management commentary and results was disclosed in this transcript.
